Related Experiment Video
Updated: Jun 20, 2026
10:42
Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over
C Basford1, N Forraz, S Habibollah
1Newcastle Centre for Cord Blood, Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK.
Cell Proliferation
|September 18, 2009
Summary
A new method, PrepaCyte-CB, offers superior umbilical cord blood (UCB) separation compared to the traditional Hetastarch method. PrepaCyte-CB improves nucleated and CD34+ cell recovery and is more efficient at removing red blood cells.
Area of Science:
- Stem cell research
- Hematology
- Biotechnology
Background:
- The standard method for umbilical cord blood (UCB) separation is Hetastarch, a mechanical process.
- Hetastarch can cause red blood cell agglutination, potentially impacting cell recovery.
Purpose of the Study:
- To evaluate a novel separation method, PrepaCyte-CB, against Hetastarch.
- This evaluation was part of an FDA-approved clinical study.
Main Methods:
- Nucleated cell recovery
- CD34+ cell recovery
- Red blood cell reduction
- Colony forming unit potential assessment
- Flow cytometry
- Sterility testing
Main Results:
- PrepaCyte-CB demonstrated higher recovery of nucleated cells (72.03%) versus Hetastarch (58.09%).
- PrepaCyte-CB showed improved recovery of CD34+ hematopoietic progenitor cells (76%) compared to Hetastarch (64.19%).
- PrepaCyte-CB was significantly more effective in reducing red blood cells and hemoglobin (12-fold greater efficiency).
Conclusions:
- PrepaCyte-CB provides superior umbilical cord blood separation compared to Hetastarch.
- The novel method offers faster, more reliable separation with better cell yields.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:19Multipotency of Hematopoietic Stem Cells
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...